GlassScriptPhysician profile
Todd Patrick Stachowiak
NPI 1831166768
$12,610.43
in general payments reported to CMS, 2019-2025
60 companies · $2,918 in 2025
The $2,918 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,371 · 2022: $2,609 · 2023: $2,034 · 2024: $2,677 · 2025: $2,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,629.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,136.53 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,719.18 | 2021-2025 | |
| Novo Nordisk INC | $1,065.55 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,055.23 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $586.96 | 2022-2025 | Caplyta |
| Amgen INC. | $464.34 | 2021-2025 | Repatha, Repatha, Otezla |
| Vanda Pharmaceuticals INC. | $398.35 | 2021-2025 | Fanapt |
| Glaxosmithkline, LLC. | $368.61 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $356.99 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $317.61 | 2021-2025 | Rexulti, Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.13 | 2021-2024 | Jardiance, Ofev, Synjardy |
| Janssen Pharmaceuticals, INC | $266.48 | 2021-2023 | Xarelto |
| Axsome Therapeutics, INC. | $237.14 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $207.06 | 2022-2025 | Vivitrol, Vivitrol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.78 | 2022-2025 | Xifaxan |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $197.15 | 2021-2023 | Ajovy |
| Qol Medical, LLC | $188.77 | 2021-2025 | Sucraid, Sucraid |
| Antares Pharma, INC. | $182.78 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceuticals, INC. | $162.36 | 2021 | |
| Amarin Pharma, INC. | $152.48 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $149.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $140.95 | 2021-2023 | |
| Astellas Pharma US INC | $106.08 | 2021-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $105.97 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $104.73 | 2021-2024 | Trintellix |
| Scilex Pharmaceuticals INC. | $91.53 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $88.96 | 2021-2023 | |
| Biogen, INC. | $81.49 | 2023-2025 | Spinraza, Skyclarys |
| Paratek Pharmaceuticals, INC. | $75.97 | 2022-2023 | Nuzyra |
| Medtronic, INC. | $69.00 | 2023 | Interstim |
| Abbott Laboratories | $68.64 | 2022-2023 | Freestyle Libre 2 |
| Grifols USA, LLC | $66.68 | 2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $64.84 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $61.42 | 2024 | Voquezna |
| Exact Sciences Corporation | $59.25 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $57.64 | 2023-2024 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $53.74 | 2022-2024 | Eliquis |
| Pfizer INC. | $53.21 | 2021-2025 | |
| Corcept Therapeutics | $51.50 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $50.67 | 2025 | Nexletol |
| Halozyme INC | $40.73 | 2023 | |
| Jazz Pharmaceuticals INC. | $34.94 | 2022 | |
| Seqirus USA INC | $33.50 | 2024-2025 | Flucelvax, Fluad |
| Verity Pharmaceuticals INC. | $28.25 | 2025 | Tlando |
| Tolmar, INC. | $27.54 | 2024 | |
| Ani Pharmaceuticals, INC. | $25.00 | 2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.55 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $24.26 | 2024 | |
| Avanir Pharmaceuticals, INC. | $23.81 | 2022 | |
| Endo Pharmaceuticals INC. | $21.46 | 2021 | |
| Dexcom, INC. | $20.06 | 2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $18.27 | 2021 | |
| Sumitomo Pharma America, INC. | $18.12 | 2025 | Gemtesa |
| Lundbeck LLC | $16.60 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $16.06 | 2022 | |
| Zealand Pharma US, INC. | $15.01 | 2022 | |
| Almatica Pharma LLC | $14.22 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.15 | 2021 | Tlando, Xyosted |
| Upsher-Smith Laboratories LLC | $13.73 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Stachowiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.